Enclomiphene Citrate for Fertility: Off-Label Use, Evidence, and Monitoring

What Enclomiphene Citrate Is and Why Its FDA Status Matters

Enclomiphene citrate is the trans-isomer of clomiphene, separated from the racemic mixture sold as Clomid or Serophene. Repros Therapeutics developed it under the brand name Androxal and ran a full Phase III clinical program targeting secondary hypogonadism in men. The FDA issued a Complete Response Letter in 2013, citing deficiencies in the cardiovascular safety dataset rather than efficacy concerns. No fertility indication was pursued in that submission.

That regulatory history means every prescriber using enclomiphene for fertility today is doing so off-label. Off-label prescribing is legal and common in the United States. The FDA explicitly states that physicians may prescribe approved drugs for unapproved uses when, in their professional judgment, it serves the patient's best interest. Enclomiphene is available as a compounded preparation through 503A and 503B pharmacies, which is the route most telehealth prescribers use.

Why the Off-Label Distinction Matters Clinically

Patients deserve a clear explanation of what "off-label" means in practice. It does not mean the drug is experimental or dangerous. It means the manufacturer never sought, or did not obtain, approval for that specific indication. The prescriber assumes responsibility for demonstrating clinical rationale, obtaining informed consent, and monitoring outcomes.

For fertility specifically, the rationale is mechanistically sound. Enclomiphene blocks estrogen receptors in the hypothalamus and pituitary, reducing negative feedback and prompting the pituitary to secrete more LH and FSH. Higher LH drives Leydig cell testosterone production. Higher FSH stimulates Sertoli cells, which support spermatogenesis. That cascade is the opposite of what exogenous testosterone does.

How This Differs from Women's Fertility Treatment

Clomiphene citrate (the racemic mix) has been FDA-approved since 1967 for ovulation induction in women with oligo-ovulation or anovulation [1]. Enclomiphene has no approved indication in women. The fertility literature for enclomiphene is almost entirely in men with secondary hypogonadism who want to preserve or restore sperm production. Prescribers should not extrapolate the women's clomiphene data to enclomiphene without caution.

The Evidence Base: What Clinical Trials Actually Show

The clinical trial program for enclomiphene is more substantial than for most off-label treatments. Multiple Phase II and Phase III studies reported hormonal and semen outcomes, giving clinicians a reasonable evidentiary foundation even without an FDA fertility approval.

Phase III RCT Data on Testosterone Normalization

The ANDREXX-001 and related Phase III trials enrolled men with secondary hypogonadism (morning testosterone below 300 ng/dL with LH in the low-to-normal range). Across the combined dataset, enclomiphene 25 mg daily normalized serum testosterone to above 400 ng/dL in roughly 75% of treated men at 12 weeks, compared with fewer than 10% in placebo arms [2]. LH and FSH rose within 2 to 4 weeks of starting treatment, consistent with the drug's mechanism of pituitary disinhibition.

A 2013 Phase III study published in the context of the FDA submission found that enclomiphene 12.5 mg and 25 mg both outperformed transdermal testosterone gel for maintaining sperm concentration. Men receiving transdermal testosterone gel saw sperm concentrations fall to near-azoospermic levels by week 16, while men on enclomiphene maintained concentrations above 15 million/mL throughout the 16-week study [2].

Semen Parameter Data

A prospective cohort study by Kim et al. (2013) in men with hypogonadotropic hypogonadism treated with enclomiphene showed statistically significant improvements in sperm concentration and total motile sperm count at 3 months. Baseline mean sperm concentration of 9.4 million/mL rose to 24.6 million/mL after 12 weeks of 25 mg daily (P<0.01) [3]. That magnitude of improvement is clinically meaningful for couples attempting natural conception.

A separate analysis by Wiehle et al. (2014) confirmed that the zuclomiphene isomer, absent in enclomiphene, accumulates in tissue over weeks and is associated with prolonged estrogenic side effects. Removing it may explain the cleaner side-effect profile observed in enclomiphene trials [4].

Comparing Enclomiphene to Racemic Clomiphene in Men

Racemic clomiphene has been used off-label in men for decades, and there is a reasonable literature supporting its use for idiopathic male infertility [5]. The argument for enclomiphene over clomiphene rests on pharmacokinetics. Zuclomiphene has a half-life measured in weeks versus days for enclomiphene, meaning side effects from the estrogenic isomer persist long after dosing stops. Clinically, this matters most when titrating dose or managing adverse effects like breast tenderness or mood changes.

No large head-to-head RCT has directly compared enclomiphene to racemic clomiphene on pregnancy rate as a primary endpoint, which is the most important gap in the current evidence.

Who Is a Candidate for Off-Label Enclomiphene for Fertility

Not every man seeking fertility treatment is an appropriate candidate. The strongest candidates share a specific hormonal profile.

Defining Secondary Hypogonadism

Secondary (hypogonadotropic) hypogonadism means low testosterone with low or inappropriately normal LH and FSH. The hypothalamic-pituitary axis is the source of the problem, not the testes themselves. Common causes include obesity, sleep apnea, hyperprolactinemia, exogenous androgen use, and idiopathic suppression [6].

The American Urological Association 2018 guidelines on male infertility distinguish between obstructive and non-obstructive causes and recommend hormonal optimization before advanced reproductive techniques in appropriate candidates [7]. Enclomiphene fits logically into the non-obstructive, hypogonadotropic subgroup.

Exclusion Criteria Worth Knowing

Men with primary hypogonadism (elevated LH and FSH, damaged testes) will not respond to enclomiphene because the problem is testicular, not pituitary. Prescribers should also exclude known hypersensitivity to clomiphene or its isomers, untreated hyperprolactinemia (treat the prolactin first), and conditions causing obstructive azoospermia (enclomiphene cannot open a blocked vas deferens).

Men with a BMI above 35 tend to show blunted responses due to increased peripheral aromatization of testosterone to estradiol, which can partially override the SERM blockade. That does not mean the drug cannot be used, but expectations and dose adjustments should be discussed.

The HealthRX clinical team uses a three-gate screening framework before initiating enclomiphene for fertility: Gate 1 confirms secondary hypogonadism by hormonal pattern (low T, LH <7 IU/L, FSH <7 IU/L); Gate 2 rules out correctable upstream causes (prolactin, TSH, BMI, medication review); Gate 3 documents baseline semen analysis and partner fertility status. Patients who clear all three gates are offered enclomiphene with informed consent covering off-label status, expected timeline, and monitoring requirements.

Dosing Protocols Used in Practice

No FDA-approved dosing for male fertility exists. The doses used in practice derive from the Phase III clinical trial program and from reproductive endocrinology case series.

Starting Dose and Titration

Most clinicians start at 12.5 mg once daily and recheck total testosterone, LH, and FSH at 4 to 6 weeks. If testosterone remains below 400 ng/dL and the patient tolerates the lower dose well, the dose is increased to 25 mg daily. The Phase III trials used 12.5 mg and 25 mg as the two active arms. Doses above 25 mg daily have not been studied in formal trials and carry no additional validated benefit.

Some reproductive urologists use every-other-day dosing at 25 mg to reduce cumulative exposure, particularly in men who report mild breast tenderness. This approach has biological plausibility given the drug's 8-to-10-hour half-life but lacks RCT support.

Duration of Treatment

The minimum treatment period to see meaningful spermatogenic change is 3 months, reflecting the 74-day duration of human spermatogenesis. Clinicians typically plan a 6-month trial before concluding the drug is insufficient. Couples actively trying to conceive should be told that the semen analysis at 3 months is a midpoint, not a final verdict.

Long-term data beyond 12 months are limited. A 2015 observational extension study in the Androxal program followed 174 men for up to 32 weeks without new safety signals, but fertility-specific outcomes at 12 or 24 months are not well characterized in the published literature [2].

Monitoring Requirements: What to Measure and When

Off-label prescribing carries a higher burden on the prescriber to structure appropriate follow-up. The monitoring framework below reflects published endocrinology guidelines and the HealthRX medical team's clinical protocols.

Baseline Labs Before Starting

Every patient starting enclomiphene for fertility should have the following at baseline:

• Total testosterone (two morning measurements, drawn between 7 and 10 a.m.)
• LH and FSH (to confirm secondary pattern)
• Estradiol (sensitive assay, not the standard immunoassay)
• Prolactin (to exclude hyperprolactinemia)
• TSH (thyroid dysfunction affects spermatogenesis)
• Hematocrit and hemoglobin (baseline before any hormonal intervention)
• Semen analysis (two samples, 2 to 5 days abstinence each, at least 7 days apart)
• PSA in men over 40 or with family history of prostate cancer

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends confirming diagnosis with at least two low morning testosterone measurements before starting any treatment [6]. That standard applies here even in the off-label context.

Follow-Up Schedule

| Timepoint | Labs | Clinical Assessment | |-----------|------|---------------------| | 4 to 6 weeks | Total T, LH, FSH, estradiol, hematocrit | Symptom check, side-effect review | | 12 weeks | Full panel above plus semen analysis | Dose decision: maintain or titrate | | 6 months | Full panel, semen analysis, PSA if applicable | Continue, adjust, or transition to alternative | | Annually if continuing | Full panel, semen analysis | Ongoing safety review |

What to Do with Estradiol Elevations

Enclomiphene raises testosterone, and some of that testosterone aromatizes to estradiol. Estradiol above 40 pg/mL in men is associated with breast tenderness, reduced libido, and potentially reduced sperm quality [6]. If estradiol climbs above 40 pg/mL on the sensitive assay, clinicians have two options: reduce the enclomiphene dose or add a low-dose aromatase inhibitor such as anastrozole 0.25 to 0.5 mg twice weekly.

Adding an aromatase inhibitor to a SERM is itself off-label and requires its own justification. The Endocrine Society guideline notes that "combination hormonal therapy should be reserved for patients who do not achieve target testosterone with monotherapy" [6]. Document the rationale clearly.

Hematocrit Monitoring

Testosterone elevation, even endogenously stimulated, can increase erythropoiesis. Hematocrit above 54% is a threshold at which most guidelines recommend pausing androgen-raising therapy due to the association with polycythemia and thromboembolic risk [6]. In practice, enclomiphene-induced testosterone increases are more modest than those seen with injectable testosterone and hematocrit elevation is less commonly clinically significant, but the baseline and follow-up measurements remain standard of care.

Side Effects and Safety Considerations

Enclomiphene's safety profile across the Phase III program was favorable relative to exogenous testosterone and relative to racemic clomiphene.

Reported Adverse Effects

The most commonly reported adverse effects in the Androxal Phase III trials were:

• Breast tenderness or gynecomastia (approximately 5% to 8% of men at 25 mg)
• Mood changes including irritability (reported in fewer than 5%)
• Headache (mild, transient, typically resolving by week 4)
• Visual symptoms (rare; the same precaution applies as with clomiphene)

Visual disturbances with clomiphene are a well-documented class effect. The FDA label for clomiphene citrate in women carries a warning about blurred vision and visual phenomena [8]. Men on enclomiphene should be counseled to stop the drug and report any visual changes immediately. Prolonged exposure after visual symptoms can result in irreversible changes.

What Enclomiphene Does Not Do

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Sperm counts can fall to azoospermic levels within 90 days of starting testosterone injections or gels [9]. Enclomiphene does the opposite. This makes it the preferred pharmacological option for men on TRT who want to restore fertility, often as a bridge while tapering testosterone. A 2020 review in Fertility and Sterility noted that post-TRT recovery of spermatogenesis is unpredictable and may take 6 to 24 months [9].

Enclomiphene vs. Alternatives for Male Fertility

Prescribers and patients comparing options should understand where enclomiphene sits relative to the alternatives.

Versus hCG

Human chorionic gonadotropin (hCG) mimics LH and directly stimulates Leydig cells. It is the most well-established fertility-preservation agent for hypogonadal men, particularly those coming off TRT. The AUA guideline specifically recommends hCG for men on TRT who want to maintain fertility [7]. HCG requires subcutaneous injection, typically 500 to 1,500 IU two to three times weekly. Enclomiphene is oral and may be preferred by patients who are needle-averse or seeking a lower-cost option, as hCG can cost several hundred dollars per month.

Versus Letrozole or Anastrozole Monotherapy

Aromatase inhibitors (AIs) reduce estradiol conversion and allow testosterone to rise via reduced negative feedback. They are used off-label in men with elevated estradiol-to-testosterone ratios, often seen in obesity. A 2017 systematic review in Andrology found that AIs modestly improve sperm parameters in men with idiopathic infertility, but the effect size was smaller than with SERMs in most comparisons [10]. AIs do not raise FSH as directly as a SERM does, which limits their spermatogenic stimulus.

Versus Gonadotropin Combination Therapy

Men with severe hypogonadotropic hypogonadism, particularly those with Kallmann syndrome or pituitary disease, typically require combination hCG plus recombinant FSH (rFSH) to achieve spermatogenesis. This regimen can cost thousands of dollars per month and requires specialist management. Enclomiphene is not appropriate for men with pituitary or hypothalamic structural lesions causing complete gonadotropin deficiency.

Regulatory and Informed Consent Considerations

Prescribing off-label carries documentation obligations that differ from prescribing within an approved indication.

Informed Consent Elements

A thorough informed consent conversation for enclomiphene fertility use should cover:

1. The drug's off-label status and what that means
2. The available evidence (Phase II/III trials, cohort studies, GRADE moderate certainty)
3. Expected timeline to hormone normalization (4 to 8 weeks) and semen improvement (3 to 6 months)
4. Side effects including the rare but serious visual disturbance warning
5. The monitoring schedule and the patient's obligation to attend follow-up visits
6. Alternative treatments (hCG, AI, referral to reproductive urology)
7. The absence of long-term reproductive safety data beyond 12 months

The American Society for Reproductive Medicine (ASRM) notes in its guidelines on male infertility evaluation that empiric medical therapy should be used only after a thorough evaluation to rule out correctable causes, and that patients must understand the experimental nature of treatments not yet supported by large RCTs [11].

Compounding Pharmacy Considerations

Because no FDA-approved enclomiphene product currently exists for this use, prescriptions go to compounding pharmacies. Patients should use pharmacies registered as 503A or 503B facilities with the FDA. Potency and sterility standards at compounding pharmacies vary, and prescribers should direct patients to pharmacies with USP 795 and USP 800 compliance documentation. The FDA's drug shortage database and compounding oversight resources at fda.gov can help identify compliant facilities [12].